The role of sensory innervation in the regulation of liver physiology and the pathogenesis of cholestatic liver disease are undefined. Biliary proliferation has been shown to be coordinately controlled by parasympathetic and sympathetic innervation of the liver. The aim of our study was to address the role of the sensory neuropeptide calcitonin gene-related peptide (a-CGRP) in the regulation of cholangiocyte proliferation during cholestasis induced by extrahepatic bile duct obstruction (BDL). Our study utilized a knockout (KO) mouse model, which lacks the sensory neuropeptide a-CGRP. Wildtype (WT) and a-CGRP KO mice were subjected to sham surgery or BDL for 3 and 7 days. In addition, immediately after BDL, WT and KO mice were administered the CGRP receptor antagonist (CGRP 8-37 ) for 3 and 7 days by osmotic minipumps. Liver sections and isolated cholangiocytes were evaluated for proliferation markers. Isolated WT BDL (3 days) cholangiocytes were stimulated with a-and b-CGRP and evaluated for proliferation and cAMP-mediated signaling. Lack of a-CGRP inhibits cholangiocyte proliferation induced by BDL at both 3 and 7 days. BDL-induced cholangiocyte proliferation in WT mice was associated with increases of circulating a-CGRP levels. In vitro, a-and b-CGRP stimulated proliferation in purified BDL cholangiocytes, induced elevation of cAMP levels, and stimulated the activation of cAMPdependent protein kinase A and cAMP response element binding protein DNA binding. In conclusion, sensory innervation of the liver and biliary expression of a-CGRP play an important role in the regulation of cholangiocyte proliferation during cholestasis.
Cholangiocytes are the target cells in cholangiopathies including primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC). 1 In rat models of experimental cholestasis including bile duct ligation (BDL), cholangiocyte proliferation is associated with enhanced intracellular cyclic adenosine 3 0 ,5 0 -monophosphate (cAMP) levels. 1, 2 Cholangiocytes display neuroendocrine phenotypes during cholestatic liver diseases and secrete neural factors and respond to neuropeptides with alterations in proliferation. 1, [3] [4] [5] [6] [7] [8] Interruption of parasympathetic and sympathetic innervation decreases cholangiocyte cAMP levels and proliferation, and induces biliary apoptosis in BDL rats. 4, 7 Administration of cAMP-agonists reverses the decrease in cholangiocyte proliferation and the increase in cholangiocyte apoptosis induced by parasympathetic and sympathetic denervation. 4, 7 In the liver, two afferent nerve pathways have been identified: the vagal afferent nerve pathway and the spinal afferent nerve pathway (which runs through the dorsal root ganglion, DRG). 9 Sensory nerves also possess an efferent function that is mediated by the release of sensory neuropeptides (ie, a-calcitonin gene-related peptide, a-CGRP) from their peripheral terminals in tissues they innervate, regulating cellular functions independent of sensation. 10 In rat and mouse liver, CGRPpositive innervation is present as dense networks in the fibromuscular layer of the biliary tree, surrounding the portal vein, and in the stromal compartment of portal areas. a-CGRP is generated from the calcitonin gene transcript, which produces calcitonin in the thyroid C cells and a-CGRP in the sensory neurons. 13 The predominant site of a-CGRP synthesis and storage is in the sensory neurons of the DRG, which terminate peripherally on tissues innervated by the sensory nervous system. 14 Another isoform, b-CGRP, is generated from a separate gene. 15 b-CGRP differs from a-CGRP by three amino acids in rats and one in humans. 15 a-and b-CGRP are postulated to exert distinct hemodynamic and gastric effects in man, respectively. 16 CGRP signals via the G-protein-coupled, calcitonin-like receptor (CLR). 17 CLR requires a receptor activity-modifying protein (RAMP) to be functionally active. 18 The RAMP family of proteins is comprised of three members: RAMP-1, -2, and -3. RAMP(s) function as accessory proteins that regulate the trafficking of CLR to the cell membrane and the pharmacological specificity of CLR. 19 Both a-and b-CGRP signal through the CLR/RAMP1 receptor. 19 A third protein, receptor component protein (RCP), 20, 21 is required for CLR signaling. RCP is an accessory protein required to couple the CLR/RAMP complex to intracellular signaling. 20, 21 Binding of CGRP to the CLR/RAMP1/RCP receptor complex leads to increased cAMP levels via Ga s -dependent adenylyl cyclase activation resulting in activation of cAMP-dependent protein kinase A (PKA) and cAMP response element binding protein (CREB), 22, 23 which is a key pathway stimulating cholangiocyte proliferation. 24 The role of sensory innervation and neuropeptides in the regulation of cholangiocyte pathophysiology is unknown.
MATERIALS AND METHODS Materials
Reagents were purchased from Sigma Chemical Co. (St Louis, MO, USA) unless otherwise indicated. Rat a-and b-CGRP were purchased from Phoenix Pharmaceuticals, Inc. (Belmont, CA, USA). The antibody against proliferating cell nuclear antigen (PCNA) was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The following antibodies were used for CGRP receptor protein immunohistochemistry in liver sections: (i) NY1024, a rabbit polyclonal antibody raised against the peptide CWNDVAAGTESMQ of mouse CLR; (ii) 1065, a chicken polyclonal antibody raised against the peptide EEQIEALLHTVT of mouse RCP; and (iii) RAMP 1 (Santa Cruz). The following antibodies were used for CGRP receptor protein immunoblotting in purified cholangiocytes: (i) NY1045, a rabbit polyclonal raised against the peptide LGVTRNKIMT of mouse CLR; (ii) NY1020 is a rabbit polyclonal raised against the peptide MVTACRDPDYGTL of mouse RAMP1, and (iii) NY1047 is a rabbit polyclonal raised against the peptide GPEDEQSKSTSND of mouse RCP. The mouse anti-cytokeratin-7 (CK-7) antibody (clone RCK105) was purchased from Caltag Laboratories Inc. (Burlingame, CA, USA). RIA kits for the determination of intracellular cAMP and D-myo-inositol 1,4,5-trisphosphate (IP 3 ) levels were purchased from GE Healthcare (Arlington Heights, IL, USA).
Animal Models
A a-CGRP knockout (KO) mouse model (20-25 g ) was used. This is a homozygous KO model on a C57BL/6 background. The mouse model lacking the a-CGRP/CT gene was generated as described. 25 In addition, age-matched male C57BL/6 (wild type, WT) mice were purchased from Charles River (Wilmington, MA, USA). Studies were performed in: (i) sham-operated (normal) mice and (ii) WT or a-CGRP KO mice that (immediately after BDL) were treated with saline or the CGRP receptor antagonist, CGRP (0.55 mg/kg body weight/day by IP-implanted Alzet s minipumps) 26 for 3 or 7 days. BDL was performed as described. 27 Study protocols were performed in compliance with the institutional guidelines.
Cholangiocyte Isolation
Isolated cholangiocytes (95-100% pure by CK-7 immunohistochemistry) were obtained by immunoaffinity separation 24, 28, 29 with a monoclonal antibody, rat IgG2a (provided by Dr R Faris, Providence, RI, USA), against an antigen expressed by cholangiocytes. In vitro studies aimed to evaluate the effects of a-CGRP or b-CGRP on signal transduction were performed in purified cholangiocytes from 3-day BDL mice.
Analysis of a-CGRP in Liver Sections
Analysis of a-CGRP expression was performed in frozen liver sections (20 mm; three slides per treatment group) from normal and 3-day BDL WT and KO mice. Sections were defrosted at room temperature (RT) and fixed in 4% paraformaldehyde (in 1 Â phosphate-buffered saline, PBS), permeabilized in PBST (1 Â PBS with 0.2% triton), and blocked in 4% BSA (in PBST) for 1 h at RT. Primary antibodies for mouse anti-CK-7 (1:5) and rabbit anti-a-CGRP (1:100) were diluted in 1% BSA (in PBST). Sections were incubated overnight at 41C and washed three times for 10 min each with 1 Â PBST at RT. Sections were incubated with secondary antibodies (Cy2 anti-mouse (1:50) and Cy3 anti-rabbit (1:50); Jackson Immunochemicals, West Grove, PA, USA) for 2 h at RT protected from light. Following incubation, the slides were washed in PBST at RT and cover-slipped with Antifade gold containing 4V,6-diamidino-2-phenylindole (DAPI) as a counterstain (Molecular Probes, Eugene, OR, USA). Images were visualized using an Olympus IX-71 (Tokyo, Japan) confocal microscope.
a-CGRP, b-CGRP, and CGRP Receptor Component Expression The expression of CGRP receptor components (CLR, RCP, and RAMP 1) and a-CGRP and b-CGRP were evaluated by: (i) immunohistochemistry in paraffin-embedded liver sections (n ¼ 3 per group, 5 mm thick); (ii) immunoblots in protein (40 mg) from whole cholangiocyte lysates; and (iii) mRNA expression by real-time PCR in total RNA (0.75 mg) from cholangiocytes from WT and KO normal and 3-day BDL mice. Immunohistochemistry for the CGRP receptor proteins, CLR, RCP, and RAMP 1, in liver sections was performed as follows. After deparaffinization, endogenous peroxidase activity was quenched with methanol-peroxide solution (0.3% hydrogen peroxide: 80% methanol solution, Santoku Chemical Industries, Tokyo, Japan). Sections were hydrated in graded alcohol and rinsed in 1 Â PBS, before applying the antibody specific for CGRP receptor proteins (1:400) or nonimmune serum at 41C overnight. Sections were rinsed with 1 Â PBS for 5 min, and incubated with the appropriate secondary biotinylated antibodies (Nichirei, Tokyo, Japan), then developed with NovaRed (Vector Laboratories, Burlingame, CA, USA). The specimens were observed using optical microscopy (Nikon, Tokyo, Japan) equipped with CCD camera and digitizer (Nikon, Tokyo, Japan). Immunoblots were performed as described. 24 Protein loading was normalized by immunoblots for b-actin. 30 Images of the bands were obtained using a phospho-imager, Storm 860, Amersham Biosciences (Piscataway, NJ, USA) and subsequently densitometry was carried out using Scion Imaging Software (Frederick, MD, USA).
To evaluate the gene expression of a-CGRP, b-CGRP, and CGRP receptor components (CLR, RCP and RAMP1) in cholangiocytes, we employed the RT 2 Real-Time assay from SuperArray (Frederick, MD, USA). RNA was extracted with the RNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA) and reverse transcribed using the Reaction Readyt First Strand cDNA synthesis kit (SuperArray, Frederick, MD, USA). SYBR Green PCR master mix (SuperArray) was utilized in the experimental assay with RT 2 PCR rat primers designed specifically for a-CGRP, b-CGRP, CLR, RCP and RAMP-1, and the housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (SuperArray, Frederick, MD, USA). Real-time RT-PCR was performed with an ABI Prism 7900HT System using a two-step PCR cycling program at 951C for 10 min followed by 40 cycles of 951C for 15 s and 601C for 1 min. A DDC t analysis was performed using normal WT cholangiocytes as the control.
Histology, Immunohistochemical Staining, and Circulating CGRP Levels For in vivo studies, we measured plasma CGRP levels, liver weight, body weight and liver to body weight ratio, and lobular morphology, necrosis and the degree of portal inflammation from the selected groups of animals. Total plasma CGRP levels were measured with a commercial EIA kit (Peninsula Laboratories, San Carlos, CA, USA). Lobular morphology, necrosis, and the degree of portal inflammation were determined by H&E staining of paraffin-embedded liver sections (three slides evaluated per group of animals, 4-5 mm thick). At least 10 different portal areas were evaluated for each parameter. For quantification of damage, the following categories were applied: 0 null; 1 limited to portal area; 2 intermediate; and 3 pan lobular. Liver sections were examined in a coded fashion by a microscope (Nikon, Tokyo, Japan) equipped with a camera. Apoptosis was evaluated by TUNEL analysis using a commercially available kit (Wako Chemicals, Tokyo, Japan). Sections were evaluated in a coded fashion using light microscopy (Nikon, Tokyo, Japan). In all, 200 cells per slide were counted in 10 nonoverlapping fields.
Analysis of Cholangiocyte Proliferation
Cholangiocyte proliferation was evaluated by measurement of the number of PCNA-and CK-7-positive cholangiocytes in liver sections, 7, 24, 31, 32 and PCNA protein expression 7, 31 in cholangiocytes from the selected group of animals. Sections were evaluated in a coded fashion using light microscopy (Nikon, Tokyo, Japan). Over 100 cholangiocytes were counted in three different fields for each group of animals.
Intracellular Signaling Mechanisms
The in vitro studies to evaluate the effects of a-CGRP or b-CGRP on proliferation and signaling were performed in cholangiocytes from 3-day BDL WT mice. The concentration of a-CGRP and b-CGRP (10 À9 M) used to stimulate purified mouse BDL cholangiocytes was in the range of that used in other in vitro studies 33, 34 and was similar to the circulating levels (pM range) of CGRP found in humans, 35 rats, 34 and mice in present studies (Table 1) . Following isolation, cholangiocytes were incubated at 371C for 1 h to regenerate membrane proteins damaged by proteolytic treatment. 36 Subsequently, we evaluated the in vitro effects of a-and b-CGRP (10 À9 M, 371C for 90 min) on PCNA protein expression in cholangiocytes from 3-day BDL WT mice. We evaluated the in vitro effects of a-and b-CGRP (10 À9 M at RT for 5 min) on cAMP and IP 3 levels of cholangiocytes from BDL mice by RIA kits. 30 We measured the effects of a-and b-CGRP (10 À9 M at 371C for 90 min) on the activity of PKA in WT BDL mouse cholangiocytes with the PepTag assay for nonradioactive detection of PKA according to the manufacturer's protocol (Promega, Madison, WI, USA). 24, 37 Finally, we measured the effect of a-and b-CGRP (10 À9 M at 371C for 90 min) on the activity and phosphorylation of CREB in purified WT BDL cholangiocytes in the absence/ presence of pretreatment with H-89 (PKA inhibitor, 10 mM).
38 Activation and phosphorylation of CREB were evaluated by a transcription factor assay kit (Active Motif, Carlsbad, CA, USA), which detects binding activity of phosphorylated CREB (Ser-133).
To evaluate whether CGRP secreted by cholangiocytes stimulates cholangiocyte proliferation by an autocrine mechanism, the supernatant of isolated cholangiocytes (after 6 h of incubation at 371C) from 3-day BDL WT and KO mice was transferred into plates containing our murine cholangiocyte cell line. 39 In addition, our murine cholangiocyte cell line was also pretreated in vitro with the CGRP receptor antagonist (CGRP 8-37 , 1 mM) for 30 min prior to the addition of the supernatant from 3-day BDL WT mice. After 24 h of incubation, cholangiocyte proliferation was evaluated by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) proliferation assay. 6, 40 This is the same approach that we have used for evaluating the stimulatory effects of nerve growth factor (NGF, present in the supernatant of primary cultures of BDL cholangiocytes) on the proliferation of normal cholangiocytes. 41 
Statistical Analysis
All data are expressed as mean7s.e.m. Differences between groups were analyzed by the Student unpaired t-test when two groups were analyzed and analysis of variance (ANOVA) when more than two groups were analyzed, followed by an appropriate post hoc test.
RESULTS

In Situ Localization of Intrahepatic a-CGRP-Positive Sensory Innervation
We performed immunofluorescence for CK-7 and CGRP in liver sections from normal and 3-day BDL WT and KO mice (Figure 1) . Interestingly, in normal and BDL WT mice, there was colocalization of a-CGRP in the areas stained positive for CK-7 ( Figure 1 ). As expected, in the liver sections of normal and 3-day BDL KO mice, there was absence of a-CGRPpositive staining in the liver sections (Figure 1 ).
Cholangiocytes Express a-CGRP, b-CGRP, and CGRP Receptor Components CGRP receptor proteins, CLR, RCP, and RAMP 1, were expressed by bile ducts from normal WT and KO mice and 3-day BDL WT and KO mice as shown by immunohistochemistry in liver sections and by immunoblotting in isolated cholangiocytes (Figure 2a and b) . Immunoblotting analysis shows that protein expression for CLR, RCP, and RAMP1 are not significantly different in cholangiocytes from the four groups of animals ( Figure 2b ). Bile ducts and isolated cholangiocytes also expressed RAMPs 2 and 3 by immunohistochemistry (not shown).
Both normal and BDL WT cholangiocytes expressed the message for a-CGRP. The message for a-CGRP was upregulated (four-fold) compared to normal WT cholangiocytes (Figure 3a) . Cholangiocytes from normal and BDL KO mice did not express a-CGRP mRNA (Figure 3a) . b-CGRP expression was detected in normal WT cholangiocytes and almost not detectable in BDL WT and normal KO cholangiocytes (Figure 3a) . However, there was an unexpected 10-fold increase in b-CGRP mRNA in cholangiocytes from BDL KO mice (Figure 3a) . Real-time RT-PCR revealed CLR mRNA expression in normal WT and KO cholangiocytes and an approximately 167-fold increase in the message for CLR in cholangiocytes from BDL WT mice compared to normal WT (Figure 3b) . In comparison, a 62-fold increase in the expression of CLR mRNA was observed in BDL KO cholangiocytes, which indicates a significant reduction in the expression of CLR in BDL KO compared to BDL WT cholangiocytes (Figure 3b ). Low levels of the RCP and RAMP 1, which are required for the function of CLR, were detected in both normal WT and KO cholangiocytes (Figure 3b) . However, the mRNA expression levels of RCP and RAMP 1 were significantly upregulated in both BDL WT and KO mice (Figure 3b ). Although we found changes in the CGRP receptor expression at the mRNA level, the changes observed at the message level did not result in significant alterations of expression at the protein level, which may be due to a number of post-transcriptional factors such as message instability. 
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Histology and Liver Weight to Body Weight Ratios No significant differences in body weight were observed in normal and BDL KO mice compared with their corresponding normal and 3-day BDL WT mice (Table 1) . Consistent with the finding that the lack of a-CGRP induces a decrease in bile duct mass, in KO BDL mice, there was a significant decrease in both liver weight and liver to body weight ratio compared to 3-day BDL WT mice (Table 1) . There were no significant differences in the degree of portal inflammation, necrosis, and lobular damage among the selected groups of animals ( Table 1) .
Lack of a-CGRP Reduces Biliary Proliferation During Cholestasis
Consistent with previous findings, 42 there was a significant increase in biliary proliferation in both 3-and 7-day BDL WT mice compared to normal WT mice ( Figure 4a and Table 2 ). In liver sections from 3-and 7-day BDL KO mice, we observed a reduction in the number of PCNA-and CK-7-positive cholangiocytes compared to 3-and 7-day BDL WT mice ( Figure 4a and Table 2 ). No significant differences were noted for the WT and KO normal mice treatment groups with respect to cholangiocyte proliferation and intrahepatic biliary mass (Figure 4a and Table 2 ). We found that the administration of CGRP to both 3-and 7-day BDL WT mice reduced the number of PCNA-and CK-7-positive cholangiocytes compared to 3-and 7-day BDL WT mice, respectively ( Table 2 ). The administration of CGRP to a-CGRP KO BDL mice that blocked b-CGRP in these mice: (i) further reduced the number of PCNA-positive cholangiocytes in 3-and 7-day a-CGRP KO BDL mice and (ii) decreased the number of CK-7-positive cholangiocytes in 7-day a-CGRP KO BDL mice (Table 2) .
In 3-day BDL KO mice, there was a concomitant increase in the number of apoptotic cholangiocytes compared to the degree of cholangiocyte apoptosis observed in 3-day BDL WT mice (Table 1) . No difference in cholangiocyte apoptosis was seen between WT and KO normal mice (Table 1) . Similarly, there was decreased PCNA protein expression in cholangiocytes from 3-day BDL KO mice compared with cholangiocytes from BDL WT mice (Figure 4b ).
Cholestasis Induced by BDL Elevates Circulating CGRP Levels
Consistent with previous studies demonstrating that circulating total CGRP levels are elevated in cirrhosis, 43, 44 we found a two-fold increase in plasma CGRP levels in 3-day BDL WT mice compared to normal WT mice ( Table 1) . As expected, we found that total circulating levels of CGRP were (Table 1) . Interestingly, we found that there was a slight but significant elevation in plasma CGRP levels in 3-day BDL KO mice compared to 3-day BDL WT mice (Table 1) .
a-and b-CGRP Stimulates Proliferation and Activates cAMP/PKA/CREB-Dependent Signaling
We evaluated the effects of both a-and b-CGRP on the proliferation of cholangiocytes from 3-day BDL WT mice. In cholangiocytes from BDL WT, a-and b-CGRP also stimulated a 1.5-and 1.4-fold increase in PCNA protein expression, respectively. a-and b-CGRP significantly increased cAMP (but not IP 3 ) levels of purified BDL cholangiocytes (Figure 5a ). a-and b-CGRP also significantly increased the activity of PKA (Figure 5b ) and DNA-binding activity of pCREB (Ser-133) (Figure 5c ). The a-and b-CGRP-induced increase in pCREB DNA-binding activity was blocked by H-89 (Figure 5c ).
BDL Cholangiocyte Supernatant Stimulates the Proliferation of Murine Cholangiocytes
We found that the supernatant from 3-day BDL WT cholangiocytes stimulated the proliferation of the murine cholangiocyte cell line 39 compared to basal unstimulated cholangiocytes ( Figure 6 ). In addition, the supernatant from 3-day BDL KO cholangiocytes had no significant effect on cholangiocyte proliferation (Figure 6 ). Also, we found that in vitro pretreatment of the murine cholangiocyte cell line with CGRP , prior to stimulation with 3-day BDL cholangiocyte supernatant, resulted in a reduction of cholangiocyte proliferation to near basal levels ( Figure 6 ).
DISCUSSION
Studies have shown that circulating levels of sensory neuropeptides such as CGRP, 43, 44 substance P, 45 and adrenomedullin 46 are elevated in human and animal models of cirrhosis. Elevations of circulating neuropeptides have been shown to alter systemic and splanchnic circulation in patients with chronic liver diseases. 47 The mechanisms regulating these events and the potential effects on cholangiocytes are not well defined. In our study, we present evidence that the sensory neuropeptide, a-CGRP, plays a key role in the regulation of biliary mass during extrahepatic cholestasis.
The presence of a-CGRP-positive sensory innervation of the vascular and biliary system of the liver suggests that these nerves play a key role in regulating biliary activity as well as hemodynamic functions. 11, 48 The presence of a-CGRP immunoreactivity in bile ducts and the upregulation of a-CGRP and CGRP receptor gene expression in isolated BDL WT cholangiocytes suggests the possibility of an autocrine signaling mechanism, which is activated by cholestasis and contributes to the proliferation of cholangiocytes similar to what we have previously described for vascular endothelial growth factor and NGF. 31, 41 In support of this concept, our data demonstrate that: (i) the supernatant (containing CGRP) from isolated 3-day BDL cholangiocytes stimulates the proliferation of mouse cholangiocytes in vitro and (ii) CGRP-induced in vitro increase in cholangiocyte proliferation is blocked by preincubation with CGRP , suggesting that an autocrine (in addition to a paracrine pathway) signaling mechanism may exist. This finding is also evident in the lack of proliferation observed when mouse cholangiocytes were stimulated in vitro with the supernatant from 3-day BDL KO mice.
Along this line, we demonstrated that bile ducts express the receptor components required for CGRP signaling and that the lack of the sensory neuropeptide, a-CGRP, significantly reduced biliary proliferation in a mouse model of extrahepatic cholestasis. Mice lacking a-CGRP during cholestasis exhibited a decrease in cholangiocyte proliferation compared to 3-and 7-day BDL WT mice. Similarly, we found that chronic administration of CGRP to BDL WT mice also resulted in decreased cholangiocyte proliferation, which would indicate an important role for the sensory neuropeptides a-and b-CGRP. To date, a double knockout model for a-and b-CGRP does not exist. To further clarify the role of b-CGRP in the regulation of cholangiocyte proliferation, we also evaluated the effects of chronic administration of CGRP (that also blocks b-CGRP) to BDL KO mice. We found that administration of CGRP reduced proliferation of cholangiocytes slightly below the levels of that observed for BDL KO mice, a finding that suggests that b-CGRP may have a minor role in the regulation of cholangiocyte proliferation. The observation that the administration of CGRP 8-37 to 3-day KO BDL mice decreased the number of PCNA-positive cholangiocytes but not ductal mass (as shown by CK-7, compared to 3-day KO BDL mice) may be explained by a simple lag in timing between the two phenomena. Changes in gene expression that ultimately result in changes in cholangiocyte proliferation has a different temporal profile to the resulting changes in ductal mass containing well-differentiated, hormone-responsive bile ducts. We believe that at day 3 of BDL, the cholangiocytes have increased the expression of the machinery required to stimulate proliferation (e.g., PCNA), but that perhaps at this time point it is too premature to see a marked difference in cholangiocyte number. Whereas, at a later time point of 7 days, there has been sufficient time for the changes in PCNA expression to translate into changes in ductal mass. These findings are in agreement with our previous studies showing that: (i) rat bile ducts at day 3 of BDL respond minimally to secretin 49 and (ii) secretin-stimulated bicarbonate-rich choleresis is evident at day 7 of BDL. 49 We demonstrated, in isolated BDL WT cholangiocytes, that both a-CGRP and b-CGRP stimulate the activation of a cAMP/PKA/CREB-dependent pathway. The findings that: (i) both a-and b-CGRP stimulated the same signaling mechanism; (ii) b-CGRP gene expression levels were elevated in BDL KO cholangiocytes; and (iii) other sensory neuropeptides, such as substance P 45 and adrenomedullin, 46 are elevated during chronic liver diseases providing an explanation for our observation of a significant but not a complete blockage of biliary proliferation during cholestasis in mice lacking a-CGRP. However, the extent of reduction of intrahepatic ductal mass observed in a-CGRP KO mice following BDL was similar to that observed in other studies. 31, 50, 51 For example, biliary proliferation induced by BDL can be partially blocked by chronic administration of gastrin via osmotic minipumps, immunoneutralization of VEGF via administration of anti-VEGF, and during ischemia induced by hepatic artery ligation. 31, 50, 51 In support of the concept that in addition to CGRP, other sensory neuropeptides regulates ductal mass, we have demonstrated that the sensory neuropeptide substance P also plays an important role in the regulation of biliary growth during BDL. We have found in KO mice lacking the NK 1 receptor (ie, substance P receptor) a similar reduction in biliary proliferation during cholestasis as that observed in a-CGRP KO mice, which indicates that both sensory neuropeptides, a-CGRP and substance P, play a coordinated role in the regulation of cholangiocyte proliferation during cholestasis. 52 Thus, the fact that a number of sensory neuropeptides coordinately regulate ductal mass provides the explanation for the partial block of proliferation observed in BDL a-CGRP KO mice. The upregulation of a-CGRP expression in cholangiocytes during cholestasis and the significant reduction in biliary proliferation in mice lacking a-CGRP attest to the importance of a-CGRP-sensory innervation in the regulation of cholangiocyte proliferation during cholestasis. This finding is supported by previous studies demonstrating that sensory neurons and enteric neurons preferentially express a-CGRP and b-CGRP, respectively. 53 We found that supernatant from 3-day BDL WT mice stimulates the proliferation of cholangiocytes compared to their basal proliferative rates. Consistent with our in vivo data, supernatant from BDL KO mice did not significantly stimulate proliferation. Indeed, the stimulation of cholangiocyte proliferation by BDL WT mouse supernatant was blocked by in vitro pretreatment with CGRP . These Figure 6 Effect of the supernatant of isolated cholangiocytes (after 6 h of incubation at 371C) from 3-day BDL WT and KO mice on the proliferation of mouse cholangiocyte cell lines. The mouse cholangiocyte cell line was also pretreated in vitro with the CGRP receptor antagonist (CGRP 8-37 , 1 mM) for 30 min prior to the addition of the supernatant from 3-day BDL WT mice. After 24 h of incubation, cholangiocyte proliferation was measured by MTS proliferation assay. We found that supernatant from 3-day BDL WT mice stimulates the proliferation of cholangiocytes compared to basal proliferative rates. Consistent with our in vivo data, supernatant from BDL KO mice did not significantly stimulate proliferation. Indeed, the stimulation of cholangiocyte proliferation by BDL WT mouse supernatant was blocked by in vitro pretreatment with CGRP . Data are mean7s.e.m. of seven experiments. *Po0.05 vs basal.
findings suggest that cholangiocyte proliferation is controlled at least in part by an autocrine mechanism in addition to paracrine signaling via sensory neurons.
We found that cholestasis induced by extrahepatic bile duct obstruction for 3 days stimulated a two-fold increase in total CGRP plasma levels. It is not known if the exact mechanism controlling the increase of plasma CGRP levels is due to a direct effect of BDL or an indirect compensatory mechanism. Future studies will be aimed to address if increased circulating bile acid levels during cholestasis have a direct effect on CGRP release from sensory neurons. We also noted a slight increase in total CGRP plasma levels in BDL KO mice, which may be due to a compensatory increase of b-CGRP expression in enteric neurons and/or lack of b-CGRP degradation due to cholestasis. The significant reduction in biliary mass in BDL KO mice suggests that a-CGRP has a predominant role in the regulation of cholangiocyte proliferation during cholestasis. Regulation of sensory neuropeptide levels and blockage of signaling by antagonists may represent a potential treatment for cholestatic liver diseases.
